513 related articles for article (PubMed ID: 17655878)
1. Neurotoxicity studies with the monoamine oxidase B substrate 1-methyl-3-phenyl-3-pyrroline.
Ogunrombi MO; Malan SF; Terre'Blanche G; Castagnoli K; Castagnoli N; Bergh JJ; Petzer JP
Life Sci; 2007 Jul; 81(6):458-67. PubMed ID: 17655878
[TBL] [Abstract][Full Text] [Related]
2. Deuterium isotope effects for the oxidation of 1-methyl-3-phenyl-3-pyrrolinyl analogues by monoamine oxidase B.
Pretorius A; Ogunrombi MO; Terre'blanche G; Castagnoli N; Bergh JJ; Petzer JP
Bioorg Med Chem; 2008 Oct; 16(19):8813-7. PubMed ID: 18799315
[TBL] [Abstract][Full Text] [Related]
3. Correlation between the neostriatal content of the 1-methyl-4-phenylpyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to several strains of mice.
Giovanni A; Sieber BA; Heikkila RE; Sonsalla PK
J Pharmacol Exp Ther; 1991 May; 257(2):691-7. PubMed ID: 2033514
[TBL] [Abstract][Full Text] [Related]
4. Interactions of 1-methyl-3-phenylpyrrolidine and 3-methyl-1-phenyl-3-azabicyclo[3.1.0]hexane with monoamine oxidase B.
Pretorius A; Ogunrombi MO; Fourie H; Terre'blanche G; Castagnoli N; Bergh JJ; Petzer JP
Bioorg Med Chem; 2010 Jun; 18(11):4111-8. PubMed ID: 20451395
[TBL] [Abstract][Full Text] [Related]
5. Characterization of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) binding sites in C57BL/6 mouse brain: mutual effects of monoamine oxidase inhibitors and sigma ligands on MPTP and sigma binding sites.
Itzhak Y; Mash D; Zhang SH; Stein I
Mol Pharmacol; 1991 Mar; 39(3):385-93. PubMed ID: 1848660
[TBL] [Abstract][Full Text] [Related]
6. Structure-activity study of the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity. I. Evaluation of the biological activity of MPTP analogs.
Youngster SK; Sonsalla PK; Sieber BA; Heikkila RE
J Pharmacol Exp Ther; 1989 Jun; 249(3):820-8. PubMed ID: 2786564
[TBL] [Abstract][Full Text] [Related]
7. Species-dependent differences in monoamine oxidase A and B-catalyzed oxidation of various C4 substituted 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridinyl derivatives.
Inoue H; Castagnoli K; Van Der Schyf C; Mabic S; Igarashi K; Castagnoli N
J Pharmacol Exp Ther; 1999 Nov; 291(2):856-64. PubMed ID: 10525109
[TBL] [Abstract][Full Text] [Related]
8. D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity.
Muralikrishnan D; Samantaray S; Mohanakumar KP
Synapse; 2003 Oct; 50(1):7-13. PubMed ID: 12872288
[TBL] [Abstract][Full Text] [Related]
9. Development of fluorinated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analogs with potent nigrostriatal toxicity for potential use in positron emission tomography studies.
Harik SI; Riachi NJ; Hritz MA; Berridge MS; Sayre LM
J Pharmacol Exp Ther; 1993 Aug; 266(2):790-5. PubMed ID: 8355208
[TBL] [Abstract][Full Text] [Related]
10. Depletion of heart norepinephrine in mice by some analogs of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine).
Fuller RW; Hemrick-Luecke SK
Res Commun Chem Pathol Pharmacol; 1987 May; 56(2):147-56. PubMed ID: 3496637
[TBL] [Abstract][Full Text] [Related]
11. Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 2: Central administration of 1-methyl-4-phenylpyridinium.
Giovanni A; Sonsalla PK; Heikkila RE
J Pharmacol Exp Ther; 1994 Sep; 270(3):1008-14. PubMed ID: 7932148
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity study of the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity. II. Evaluation of the biological activity of the pyridinium metabolites formed from the monoamine oxidase-catalyzed oxidation of MPTP analogs.
Youngster SK; Nicklas WJ; Heikkila RE
J Pharmacol Exp Ther; 1989 Jun; 249(3):829-35. PubMed ID: 2786565
[TBL] [Abstract][Full Text] [Related]
13. Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 1: Systemic administration.
Giovanni A; Sieber BA; Heikkila RE; Sonsalla PK
J Pharmacol Exp Ther; 1994 Sep; 270(3):1000-7. PubMed ID: 7932147
[TBL] [Abstract][Full Text] [Related]
14. Assessment of structural requirements for the monoamine oxidase-B-catalyzed oxidation of 1,4-disubstituted-1,2,3,6-tetrahydropyridine derivatives related to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Mabic S; Castagnoli N
J Med Chem; 1996 Sep; 39(19):3694-700. PubMed ID: 8809158
[TBL] [Abstract][Full Text] [Related]
15. Iron-mediated bioactivation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in glial cultures.
Di Monte DA; Schipper HM; Hetts S; Langston JW
Glia; 1995 Oct; 15(2):203-6. PubMed ID: 8567072
[TBL] [Abstract][Full Text] [Related]
16. Nitroindazole compounds inhibit the oxidative activation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxin to neurotoxic pyridinium cations by human monoamine oxidase (MAO).
Herraiz T; Arán VJ; Guillén H
Free Radic Res; 2009 Oct; 43(10):975-84. PubMed ID: 19669997
[TBL] [Abstract][Full Text] [Related]
17. Age-dependent effects of the 2'-methyl analog of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine: prevention by inhibitors of monoamine oxidase B.
Finnegan KT; Irwin I; Delanney LE; Langston JW
J Pharmacol Exp Ther; 1995 May; 273(2):716-20. PubMed ID: 7752075
[TBL] [Abstract][Full Text] [Related]
18. The behaviour of aryl pyrrolines with monoamine oxidase.
Williams CH; Lawson J
Neurobiology (Bp); 1999; 7(2):225-33. PubMed ID: 10591055
[TBL] [Abstract][Full Text] [Related]
19. Mitochondrial and metabolic toxicity of 1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine.
Kindt MV; Heikkila RE; Nicklas WJ
J Pharmacol Exp Ther; 1987 Sep; 242(3):858-63. PubMed ID: 3498818
[TBL] [Abstract][Full Text] [Related]
20. Characteristics of 1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the mouse.
Sonsalla PK; Youngster SK; Kindt MV; Heikkila RE
J Pharmacol Exp Ther; 1987 Sep; 242(3):850-7. PubMed ID: 2888874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
